{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:52:00Z","timestamp":1791409920324,"version":"4.3.3"},"reference-count":185,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2024\/07723-2"],"award-info":[{"award-number":["2024\/07723-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2024\/22137-2"],"award-info":[{"award-number":["2024\/22137-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110298","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:07:26Z","timestamp":1784992046000},"page":"110298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Why JAK3 selectivity matters: biology, approved JAK inhibitors, and medicinal chemistry perspectives"],"prefix":"10.1016","volume":"181","author":[{"given":"Sara","family":"Dias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Parise-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110298_bb0005","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110298_bb0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","article-title":"The JAK-STAT pathway: from structural biology to cytokine engineering","volume":"9","author":"Lv","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110298_bb0015","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/blood-2008-06-164368","article-title":"Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models","volume":"113","author":"Cornejo","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110298_bb0020","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2026.110298_bb0030","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110298_bb0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.110298_bb0040","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/nsmb.2673","article-title":"Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases","volume":"20","author":"Toms","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nsmb.2099","article-title":"The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling","volume":"18","author":"Ungureanu","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nsmb.2807","article-title":"Structural basis of recognition of interferon-\u03b1 receptor by tyrosine kinase 2","volume":"21","author":"Wallweber","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0055","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2026.110298_bb0060","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1038\/sj.onc.1210757","article-title":"Hematopoietic cytokine receptor signaling","volume":"26","author":"Baker","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110298_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112201","article-title":"Structural basis of Janus kinase trans-activation","volume":"42","author":"Caveney","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2026.110298_bb0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110298_bb0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110298_bb0080","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.3390\/ijms22115421","article-title":"Inflammation-induced tumorigenesis and metastasis","volume":"22","author":"Hibino","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110298_bb0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110298_bb0095","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in Cancer immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0100","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0105","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.3390\/ijms21238885","article-title":"The genetic basis of primary myelofibrosis and its clinical relevance","volume":"21","author":"Rumi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153712","article-title":"Cascade of immune mechanism and consequences of inflammatory disorders","volume":"91","author":"Megha","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2026.110298_bb0115","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/ijc.23173","article-title":"Inflammation and cancer: an ancient link with novel potentials","volume":"121","author":"Perwez Hussain","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110298_bb0120","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.3390\/ijms25052977","article-title":"Janus kinase 3 (JAK3): a critical conserved node in immunity disrupted in immune cell cancer and immunodeficiency","volume":"25","author":"Liongue","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00018-015-2062-4","article-title":"The common \u03b3-chain cytokine receptor: tricks-and-treats for T cells","volume":"73","author":"Waickman","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0130","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41375-021-01392-1","article-title":"PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression","volume":"36","author":"Yuan","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0135","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by \u03b3c family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0140","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.biocel.2009.09.004","article-title":"JAK3: a two-faced player in hematological disorders","volume":"41","author":"Cornejo","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0145","doi-asserted-by":"crossref","unstructured":"Lokau, J. & Garbers, C. Activating mutations of the gp130\/JAK\/STAT pathway in human diseases. in 283\u2013309 (2019). doi:https:\/\/doi.org\/10.1016\/bs.apcsb.2018.11.007.","DOI":"10.1016\/bs.apcsb.2018.11.007"},{"key":"10.1016\/j.bioorg.2026.110298_bb0150","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3390\/cancers11111646","article-title":"STAT3: an emerging therapeutic target for hepatocellular carcinoma","volume":"11","author":"Lee","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110298_bb0155","first-page":"5671","article-title":"Constitutive activation of STAT3 and cyclin D1 overexpression contribute to proliferation, migration and invasion in gastric cancer cells","volume":"9","author":"Luo","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bioorg.2026.110298_bb0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer \u2014 using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110298_bb0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110298_bb0170","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110298_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.669363","article-title":"JAK-STAT in early hematopoiesis and leukemia","volume":"9","author":"Fasouli","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0180","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1083\/jcb.200812060","article-title":"Acetylation and activation of STAT3 mediated by nuclear translocation of CD44","volume":"185","author":"Lee","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0185","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1074\/jbc.M109.040733","article-title":"STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant","volume":"285","author":"Funakoshi-Tago","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0190","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3324\/haematol.2020.271957","article-title":"MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma","volume":"106","author":"Ramis-Zaldivar","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2026.110298_bb0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ccr.2006.06.002","article-title":"Activating alleles of JAK3 in acute megakaryoblastic leukemia","volume":"10","author":"Walters","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110298_bb0200","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ajpath.2017.01.004","article-title":"Novel JAK3-activating mutations in extranodal NK\/T-cell lymphoma, nasal type","volume":"187","author":"Sim","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","article-title":"Janus kinase 3\u2013activating mutations identified in natural killer\/T-cell lymphoma","volume":"2","author":"Koo","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110298_bb0210","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/leu.2013.157","article-title":"JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma","volume":"28","author":"Bouchekioua","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0215","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0220","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/leu.2012.74","article-title":"Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia","volume":"26","author":"Bains","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0225","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110298_bb0230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110298_bb0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mc.23632","article-title":"The JAK3 Q988P mutation reveals oncogenic potential and resistance to ruxolitinib","volume":"63","author":"Lahera","year":"2024","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2026.110298_bb0240","doi-asserted-by":"crossref","first-page":"29022","DOI":"10.1074\/jbc.M115.670224","article-title":"Distinct acute lymphoblastic leukemia (ALL)-associated Janus kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK inhibitor specificities","volume":"290","author":"Losdyck","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0245","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood-2017-07-797597","article-title":"Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL","volume":"131","author":"Degryse","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110298_bb0250","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2014-04-566687","article-title":"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model","volume":"124","author":"Degryse","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110298_bb0255","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13073-017-0478-1","article-title":"Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications","volume":"9","author":"Li","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.bioorg.2026.110298_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235766","article-title":"Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene","volume":"15","author":"Mittempergher","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.110298_bb0265","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/1878-0261.12981","article-title":"Novel CTRP8-RXFP1-JAK3-STAT3 axis promotes Cdc42-dependent actin remodeling for enhanced filopodia formation and motility in human glioblastoma cells","volume":"16","author":"Glogowska","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3233","article-title":"Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: implication for JAK3 inhibition as a therapeutic approach","volume":"42","author":"Le","year":"2024","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0275","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-142078","article-title":"Germline gain-of-function JAK3 mutation in familial chronic lymphoproliferative disorder of NK cells","volume":"136","author":"Lesmana","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110298_bb0280","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3324\/haematol.2015.130179","article-title":"Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia","volume":"100","author":"Vicente","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2026.110298_bb0285","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41375-022-01558-5","article-title":"JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia","volume":"36","author":"Bodaar","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0290","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41568-022-00524-8","article-title":"Drivers of lineage plasticity","volume":"22","author":"Senft","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110298_bb0295","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bioorg.2026.110298_bb0300","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pharmthera.2018.06.006","article-title":"Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?","volume":"191","author":"Beebe","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.110298_bb0305","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.110298_bb0310","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/leu.2017.43","article-title":"Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition","volume":"31","author":"Leroy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0315","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.bioorg.2026.110298_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110298_bb0325","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors","volume":"58","author":"Vijayan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0330","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41589-022-01098-0","article-title":"Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine","volume":"18","author":"Kavanagh","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0335","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1016\/j.bmcl.2017.07.079","article-title":"Recent advances in JAK3 inhibition: isoform selectivity by covalent cysteine targeting","volume":"27","author":"Forster","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110298_bb0340","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110298_bb0345","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1021\/acs.jmedchem.0c01952","article-title":"Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof","volume":"64","author":"Davis","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0350","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1021\/jm801142b","article-title":"Examining the chirality, conformation and selective kinase inhibition of 3-((3 R,4 R)-4-methyl-3-(methyl(7H-pyrrolo[2,3- d ]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)","volume":"51","author":"Jiang","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0355","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1021\/acs.jmedchem.4c00197","article-title":"Functional and structural characterization of clinical-stage Janus kinase 2 inhibitors identifies determinants for drug selectivity","volume":"67","author":"Miao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0360","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/jm300438j","article-title":"Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors","volume":"55","author":"Kulagowski","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0365","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.chembiol.2016.10.008","article-title":"Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket","volume":"23","author":"Forster","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0370","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.bmc.2019.03.048","article-title":"Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors","volume":"27","author":"Wang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0375","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.2147\/DDDT.S379496","article-title":"Recent updates on the development of deuterium-containing drugs for the treatment of cancer","volume":"16","author":"Belete","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2026.110298_bb0380","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1021\/acs.jmedchem.8b01808","article-title":"Applications of deuterium in medicinal chemistry","volume":"62","author":"Pirali","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300591","article-title":"Structure-guided design of potent JAK1-selective inhibitors based on 4-amino-7H-pyrrolo[2,3-d]pyrimidine with anti-inflammatory efficacy","volume":"357","author":"Zhang","year":"2024","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.bioorg.2026.110298_bb0390","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0395","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110298_bb0400","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110298_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1326281","article-title":"Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy","volume":"14","author":"Wei","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0410","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3324\/haematol.2017.174482","article-title":"Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment","volume":"103","author":"Lam","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2026.110298_bb0415","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0420","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioorg.2026.110298_bb0425","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0430","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1021\/acs.jmedchem.0c00450","article-title":"Discovery of a Janus kinase inhibitor bearing a highly three-dimensional Spiro scaffold: JTE-052 (Delgocitinib) as a new dermatological agent to treat inflammatory skin disorders","volume":"63","author":"Noji","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0435","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","article-title":"Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo","volume":"64","author":"Tanimoto","year":"2015","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bioorg.2026.110298_bb0440","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.3390\/cancers13205204","article-title":"Second-generation Jak2 inhibitors for advanced prostate cancer: are we ready for clinical development?","volume":"13","author":"Beinhoff","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110298_bb0445","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110298_bb0450","unstructured":"FDA Fact Sheet for Healthcare Providers Emergency use Authorization (EUA) of Baricitinib. https:\/\/www.fda. gov\/media\/143823\/download."},{"key":"10.1016\/j.bioorg.2026.110298_bb0455","unstructured":"European Medicines Agency. Olumiant, INN-baricitinib. Annex I summary of product characteristics. European Public Assessment Report. http:\/\/www.ema.europa.eu\/docs\/en_GB\/docum ent_library\/EPAR_-_Product_Information\/human\/004085\/ WC500223723.pdf."},{"key":"10.1016\/j.bioorg.2026.110298_bb0460","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/JAA.S206387","article-title":"Profile of Baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: a short review on the emerging clinical evidence","volume":"13","author":"Napolitano","year":"2020","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.bioorg.2026.110298_bb0465","unstructured":"ASHP. Deuruxolitinib Phosphate (Monograph). https:\/\/www.drugs.com\/monograph\/deuruxolitinib-phosphate.html (2024)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0470","unstructured":"Stewart, J. Bp. Ojjaara FDA Approval History. (2023)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0475","unstructured":"Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia (2023)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0480","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0485","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1021\/jm300628c","article-title":"Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2","volume":"55","author":"Zak","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0490","unstructured":"Stewart, J. Bp. Rinvoq FDA Approval History. https:\/\/www.drugs.com\/history\/rinvoq.html (2025)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0495","unstructured":"AbbVie. AbbVie Receives FDA Approval of RINVOQ\u2122 (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis. https:\/\/www.prnewswire.com\/news-releases\/abbvie-receives-fda-approval-of-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-the-treatment-of-moderate-to-severe-rheumatoid-arthritis-300903053.html (2019)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0500","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0505","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/ph15010030","article-title":"Molecular modeling insights into upadacitinib selectivity upon binding to JAK protein family","volume":"15","author":"Taldaev","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.110298_bb0510","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/jcm12051734","article-title":"Upadacitinib for patients with rheumatoid arthritis: a comprehensive review","volume":"12","author":"Sanmart\u00ed","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bioorg.2026.110298_bb0515","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","article-title":"Filgotinib: a clinical pharmacology review","volume":"61","author":"Namour","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2026.110298_bb0520","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/ecco-jcc\/jjx002.032","article-title":"OP033 reduction of tissue pSTAT3 in Crohn\u2019s disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor","volume":"11","author":"Vermeire","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.bioorg.2026.110298_bb0525","first-page":"1987","volume":"80","author":"Dhillon","year":"2020","journal-title":"J. Filgotinib: First Approval. Drugs"},{"key":"10.1016\/j.bioorg.2026.110298_bb0530","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/pharmaceutics15020385","article-title":"Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis","volume":"15","author":"Iznardo","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.110298_bb0535","unstructured":"Pfizer Inc. U.S. FDA Approves Pfizer's CIBINQO\u00ae (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis. https:\/\/www.nasdaq.com\/press-release\/u.s.-fda-approves-pfizers-cibinqor-abrocitinib-for-adults-with-moderate-to-severe (2022)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0540","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.1021\/acs.jmedchem.7b01135","article-title":"The discovery of 3-((4-chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a highly ligand efficient and efficacious Janus kinase 1 selective inhibitor with favorable pharmacokinetic properties","volume":"60","author":"Siu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0545","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1021\/acs.jmedchem.0c00359","article-title":"Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0550","unstructured":"Incyte Corporation. Protocol INCB 52793-101 Amendment 9\/NCT02265510. https:\/\/cdn.clinicaltrials.gov\/large-docs\/10\/NCT02265510\/Prot_000.pdf (2017)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0555","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2026.110298_bb0560","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110298_bb0565","unstructured":"Advanced\/Metastatic, Pancreatic Cancer - Incyte Clinical Trials. https:\/\/www.incyteclinicaltrials.com\/study\/?id=INCB+39110-116&utm_source=chatgpt.com."},{"key":"10.1016\/j.bioorg.2026.110298_bb0570","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40265-024-02089-2","article-title":"Golidocitinib: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110298_bb0575","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0580","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1182\/blood-2025-7157","article-title":"Efficacy and safety of Golidocitinib-based first line regimen in peripheral T-cell lymphoma: a multicenter retrospective study","volume":"146","author":"Zhan","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110298_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0590","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-025-01211-1","article-title":"Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and \u201creal-world\u201d data","volume":"15","author":"Duek","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2026.110298_bb0595","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/bloodadvances.2024015365","article-title":"Fedratinib in 2025 and beyond: indications and future applications","volume":"9","author":"Coltoff","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.bioorg.2026.110298_bb0600","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","article-title":"Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"11","author":"Harrison","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0605","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1080\/14656566.2022.2135989","article-title":"Fedratinib: a pharmacotherapeutic option for JAK-inhibitor na\u00efve and exposed patients with myelofibrosis","volume":"23","author":"England","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110298_bb0610","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcph.218","article-title":"A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers","volume":"54","author":"Zhang","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0615","unstructured":"U.S. Food and Drug Administration. Integrated Review for Pacritinib (NDA 208712). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/208712Orig1s000IntegratedR.pdf (2022)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0620","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2174\/1871520623666230320120915","article-title":"First approval of pacritinib as a selective Janus associated kinase-2 inhibitor for the treatment of patients with myelofibrosis","volume":"23","author":"De","year":"2023","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0625","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JEP.S110702","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0630","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1182\/bloodadvances.2022007524","article-title":"The odyssey of pacritinib in myelofibrosis","volume":"6","author":"Venugopal","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.bioorg.2026.110298_bb0635","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41375-018-0112-2","article-title":"Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes","volume":"32","author":"Hosseini","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0640","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2018.06.014","article-title":"Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms","volume":"71","author":"Berdeja","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bioorg.2026.110298_bb0645","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1038\/bcj.2013.6","article-title":"Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F","volume":"3","author":"Ma","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2026.110298_bb0650","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"10.1016\/j.bioorg.2026.110298_bb0655","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0660","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110298_bb0665","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1437512","article-title":"Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways","volume":"15","author":"Johnson","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0670","first-page":"311","article-title":"Highly specific JAK3 inhibitors and the future of T cell lymphoma treatment","volume":"10","author":"Chen","year":"2022","journal-title":"J. Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0675","doi-asserted-by":"crossref","first-page":"10674","DOI":"10.1021\/acs.jmedchem.2c00922","article-title":"Discovery of Hexahydrofuro[3,2- b ]furans as new kinase-selective and orally bioavailable JAK3 inhibitors for the treatment of leukemia harboring a JAK3 activating mutant","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0680","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41375-017-0004-x","article-title":"Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer\/T-cell lymphoma","volume":"32","author":"Nairism\u00e4gi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0685","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2013.309","article-title":"Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies","volume":"28","author":"Ross","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110298_bb0690","doi-asserted-by":"crossref","first-page":"76793","DOI":"10.18632\/oncotarget.12529","article-title":"Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells","volume":"7","author":"Ando","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110298_bb0695","doi-asserted-by":"crossref","first-page":"17931","DOI":"10.1021\/acs.jmedchem.4c02052","article-title":"Dose\u2013response curves and the determination of IC50 and EC50 values","volume":"67","author":"Srinivasan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0700","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246277","article-title":"Optimized xenograft protocol for chronic lymphocytic leukemia results in high engraftment efficiency for all CLL subgroups","volume":"20","author":"Decker","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0705","doi-asserted-by":"crossref","first-page":"10665","DOI":"10.1021\/acs.jmedchem.8b01308","article-title":"Identification of Cyanamide-based Janus kinase 3 (JAK3) covalent inhibitors","volume":"61","author":"Casimiro-Garcia","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0710","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0715","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0720","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0725","unstructured":"Litfulo (ritlecitinib): approval letter and multidisciplinary review. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215830Orig1s000MultidisciplineR.pdf (2023)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0730","unstructured":"CHMP summary of positive opinion \u2013 Litfulo (ritlecitinib). European Medicines Agency (EMA) https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-litfulo_en.pdf (2023)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0735","unstructured":"Litfulo\u00ae (tosilato de ritlecitinibe): novo registro. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria - Anvisa https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/novos-medicamentos-e-indicacoes\/litfulo-r-tosilato-de-ritlecitinibe-novo-registro (2024)."},{"key":"10.1016\/j.bioorg.2026.110298_bb0740","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.4049\/jimmunol.175.7.4236","article-title":"The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities","volume":"175","author":"Stepkowski","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0745","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13543776.2017.1252753","article-title":"Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1","volume":"27","author":"Kettle","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110298_bb0750","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9342732","article-title":"Antitumorigenic effects of inhibiting ephrin receptor kinase signaling by GLPG1790 against colorectal Cancer cell lines in vitro and in vivo","volume":"2020","author":"Colapietro","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0755","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1021\/acs.jmedchem.5b00301","article-title":"Discovery of VX-509 (decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases","volume":"58","author":"Farmer","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0760","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.114.221176","article-title":"VX-509 (Decernotinib) is a potent and selective Janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease","volume":"353","author":"Mahajan","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2026.110298_bb0765","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an Oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0770","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s10854-023-11241-9","article-title":"Synthesis, spectral confirmation, structural interactions, electronic characteristics, docking, and dynamic stability of twin chiral carboxamide","volume":"34","author":"Mohanbabu","year":"2023","journal-title":"J. Mater. Sci. Mater. Electron."},{"key":"10.1016\/j.bioorg.2026.110298_bb0775","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2026.110298_bb0780","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","article-title":"Syk inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0785","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/1078-0432.CCR-18-1047","article-title":"Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed\/refractory B-cell malignancies","volume":"25","author":"Coffey","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110298_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105330","article-title":"Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma","volume":"116","author":"Wu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0795","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1021\/acs.jmedchem.5b00710","article-title":"Development of selective covalent Janus kinase 3 inhibitors","volume":"58","author":"Tan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00083","article-title":"Theoretical exploring selective-binding mechanisms of JAK3 by 3D-QSAR, molecular dynamics simulation and free energy calculation","volume":"7","author":"Zhu","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0805","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2174\/1871520622666220609112816","article-title":"Novel potent EGFR-JAK3 dual-target inhibitor that overcomes KRAS mutation resistance in colorectal cancer","volume":"23","author":"Wu","year":"2023","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00431","article-title":"Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3\/STAT3 signaling pathway","volume":"21","author":"Ahmad","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bioorg.2026.110298_bb0815","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.ejmech.2017.10.080","article-title":"Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma","volume":"143","author":"Ge","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103542","article-title":"JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma","volume":"95","author":"Chi","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0825","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1038\/s41598-018-23569-y","article-title":"Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis","volume":"8","author":"Pei","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110298_bb0830","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2174\/1568026615666150915111741","article-title":"Sulfur containing scaffolds in drugs: synthesis and application in medicinal chemistry","volume":"16","author":"Feng","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0835","series-title":"Covalent Janus Kinase 3 Inhibitors","first-page":"225","author":"Gehringer","year":"2020"},{"key":"10.1016\/j.bioorg.2026.110298_bb0840","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1074\/jbc.M114.595181","article-title":"Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol","volume":"290","author":"Goedken","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0845","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1016\/j.bmcl.2017.09.023","article-title":"Discovery of highly potent, selective, covalent inhibitors of JAK3","volume":"27","author":"Kempson","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110298_bb0850","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","article-title":"The \u03b3c family of cytokines: basic biology to therapeutic ramifications","volume":"50","author":"Leonard","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2026.110298_bb0855","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.chembiol.2011.01.012","article-title":"Jak1 has a dominant role over Jak3 in signal transduction through \u03b3c-containing cytokine receptors","volume":"18","author":"Haan","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0860","doi-asserted-by":"crossref","first-page":"9269","DOI":"10.3390\/ijms21239269","article-title":"Discovery of a novel class of covalent dual inhibitors targeting the protein kinases BMX and BTK","volume":"21","author":"Forster","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0865","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1039\/C9CS00720B","article-title":"Advances in covalent kinase inhibitors","volume":"49","author":"Abdeldayem","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.110298_bb0870","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.3390\/ijms24076023","article-title":"Docking and selectivity studies of covalently bound Janus kinase 3 inhibitors","volume":"24","author":"Zhong","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110298_bb0875","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1021\/acs.jmedchem.8b00571","article-title":"Development, optimization, and structure\u2013activity relationships of covalent-reversible JAK3 inhibitors based on a tricyclic imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold","volume":"61","author":"Forster","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0880","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1021\/acs.jmedchem.8b01823","article-title":"Discovery of an orally available Janus kinase 3 selective covalent inhibitor","volume":"62","author":"Shi","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0885","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2174\/1389557519666190617152011","article-title":"Current status in the discovery of covalent Janus kinase 3 (JAK3) inhibitors","volume":"19","author":"Dai","year":"2019","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0890","doi-asserted-by":"crossref","first-page":"12258","DOI":"10.1038\/ncomms12258","article-title":"Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models","volume":"7","author":"Bottos","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110298_bb0895","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.3390\/cancers13112611","article-title":"Untwining anti-tumor and immunosuppressive effects of JAK inhibitors\u2014a strategy for hematological malignancies?","volume":"13","author":"Klein","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110298_bb0900","doi-asserted-by":"crossref","first-page":"30341","DOI":"10.1074\/jbc.C600319200","article-title":"Janus kinase 3 regulates interleukin 2-induced mucosal wound repair through tyrosine phosphorylation of villin","volume":"282","author":"Kumar","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0905","doi-asserted-by":"crossref","first-page":"13976","DOI":"10.1074\/jbc.271.24.13976","article-title":"Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells","volume":"271","author":"Verbsky","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110298_bb0910","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6618924","article-title":"Mucosal epithelial Jak kinases in health and diseases","volume":"2021","author":"Kumar","year":"2021","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.bioorg.2026.110298_bb0915","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.121.316293","article-title":"Janus kinase 3 deficiency promotes vascular reendothelialization\u2014brief report","volume":"41","author":"Wang","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bioorg.2026.110298_bb0920","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1182\/blood-2019-122449","article-title":"Endothelial JAK3 expression enhances pro-hematopoietic angiocrine function of sinusoidal endothelial cells","volume":"134","author":"Barcia Dur\u00e1n","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110298_bb0925","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1080\/10428194.2019.1594220","article-title":"Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1\/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation","volume":"60","author":"Gomez-Arteaga","year":"2019","journal-title":"Leuk. Lymphoma"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:16:33Z","timestamp":1791407793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":185,"alternative-id":["S0045206826008345"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110298","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why JAK3 selectivity matters: biology, approved JAK inhibitors, and medicinal chemistry perspectives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110298"}}